Phase I research at Providence Cancer Institute
September 25, 2017
Phase I studies are the foundation for advancing cancer treatment with new agents and combinations of therapies. Providence Cancer Institute
is often able to offer patients first-in-human clinical trials of novel cancer therapies through our own investigator-sponsored trials, and through collaborations with industry sponsors and other early-phase institutions around the country and worldwide.
Our phase I trials focus largely on novel immunotherapies, but also include targeted therapies and other innovative agents. Here are two examples of the many phase I clinical trials that we currently offer in multiple cancer types:
A Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors
This study is for patients with advanced tumors or tumors that have spread, including:
• Women with triple negative breast carcinoma
• Patients with pancreatic adenocarcinoma
• Patients with non-small cell lung cancer
Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
This study is evaluating MK-1966, an antibody targeting IL-10, in combination with intralesional SD-101, a TLR-9 agonist.
This study is for patients with injectable advanced malignancies, including low-grade B cell lymphoma, melanoma, squamous cell cancer of the head and neck, and breast cancer.
Providence Cancer Institute currently offers more than 150 phase I, II and III clinical trials. New studies are added frequently. For a complete list of all current studies, please visit our website
. For more information, call 503-215-2614.
An exceptional team
The phase I research program at the Earle A. Chiles Research Institute
at Providence Cancer Institute is made up of oncology leaders, phase-I-dedicated nurses, data coordinators and lab assistants. Every person on this exceptional team is passionate about offering breakthrough therapies and the best possible treatment to our patients. World class . . . in Oregon.